Biotech Values

[onemodolar]

OCRX Please help.

1. P1 oral 002 is a positive development since it showed successful delivery of active compound into circulation.
2. higher serum concentration than Ravicti.
3.IV 002 has indication in the setting of HE in ICU when pt can not take oral medication, ie acute GI bleeding, or rapid resolution of HE is financially feasible by shortening of LOS. It can be used in any inpatient He if price can be adjusted. Pt can go home with oral 002 later.
4. Oral 002 can be combined with lactulose or Xifaxsan since the mode of action is totally different, barring there is no adverse interaction or absorption issue.
5. QD formula is crucial for oral 002 to gain the market share as maintenance therapy. compliance is one of the biggest issue here.
6. erratic serum concentration? Is it that much of problem? Rate limiting steps are metabolism in the muscle and excretion through kidneys. As an endogenous compound, does high peak level cause toxicity? does low trough level cause sub optimal reduction of Ammonia level? My "assumption" is oral preventive therapy may require far lower concentration than acute IV therapy. How much of difference in terms of Ammonia clearance capacity is there? Liver vs muscle? Which pathway is more effective target to prevent HE in the absence of Liver? Reducing production and absorption vs enhancing muscle metabolism? TIA